Careers Contact Us Legal Search for: Menu Product Pipeline TNK Therapeutics Antibody Technologies G-MAB™ ADC Bi-Specific Antibodies Collaborations Investors Events and Presentations Stock Information Corporate Governance SEC Documents News About Us Management Team Board of Directors Scientific Advisors Careers Contact Us Sorrento Therapeutics is an oncology company developing new treatments for cancer and associated pain. In December 2014, Sorrento entered into a global exclusive partnership with Conkwest, Inc., an immunotherapy company developing proprietary Neukoplast (NK-92), a Natural Killer (NK) cell-line based therapy, to jointly develop next-generation CAR.TNK immunotherapies for the treatment of cancer and infectious diseases. RTX is a non-opiate drug candidate targeting TRPV1 receptors currently in Phase 1/2 clinical studies for the treatment of intractable cancer pain. Preclinical pipeline of protein targeted therapies is driven by our core G-MAB® technology, one of the largest and most diverse fully human antibody libraries in the industry, and proprietary bi-specific and ADC technology. Next Small Molecules Targeted Therapy MYC inhibitor TRAIL modulator HIF-1a inhibitor Biologics Immunotherapy PD-1, PD-L1, CTLA-4 Bispecific Abs Targeted Therapy Anti-VEGFR2 ADC Anti-c-MET ADC Bispecific ADC Cell Therapy Adoptive Cellular Immunotherapy CAR.TNK CAR-T Supportive Care RTX Intractable Cancer Pain © 2015 Sorrento Therapeutics Privacy Policy Legal CAR.TNK, and TNK Therapeutics are trademarks owned by Sorrento Therapeutics, Inc. All other trademarks and trade names are the properties of their respective owners.